The DNA damage response (DDR) machinery becomes commonly activated in response to oncogenes and during early stages of development of solid malignancies, with an exception of testicular germ cell tumors (TGCTs). The active DDR signaling evokes cell death or senescence but this anti-tumor barrier can be breached by defects in DDR factors, such as the ATM-Chk2-p53 pathway, thereby allowing tumor progression. The DDR barrier is strongly activated in brain tumors, particularly gliomas, due to oxidative damage and replication stress. Here, we took advantage of rare human primary intracranial germ cell tumors (PIGCTs), to address the roles of cell-intrinsic factors including cell of origin, versus local tissue environment, in the constitutive DDR activation in vivo. Immunohistochemical analysis of 7 biomarkers on a series of 21 PIGCTs (germinomas and other subtypes), 20 normal brain specimens and 20 glioblastomas, revealed the following: i) The overall DDR signaling (γH2AX) and activation of the ATM-Chk2-p53 pathway were very low among the PIGCTs, reminiscent of TGCTs, and contrasting sharply with strong DDR activation in glioblastomas; ii) Except for one case of embryonal carcinoma, there were no clear aberrations in the ATM-Chk2-p53 pathway components among the PIGCT cohort; iii) Subsets of PIGCTs showed unusual cytosolic localization of Chk2 and/or ATM. Collectively, these results show that PIGCTs mimic the DDR activation patterns of their gonadal germ cell tumor counterparts, rather than the brain tumors with which they share the tissue environment. Hence cell-intrinsic factors and cell of origin dictate the extent of DDR barrier activation and also the ensuing pressure to select for DDR defects. Our data provide conceptually important insights into the role of DNA damage checkpoints in intracranial tumorigenesis, with implications for the differential biological responses of diverse tumor types to endogenous stress as well as to genotoxic treatments such as ionizing radiation or chemotherapy.

Danish Cancer Society Research Center Copenhagen Denmark

Danish Cancer Society Research Center Copenhagen Denmark; Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

University Department of Growth and Reproduction Rigshospitalet Copenhagen Denmark

University Department of Growth and Reproduction Rigshospitalet Copenhagen Denmark; Department of Pediatrics Rigshospitalet Copenhagen Denmark

Zobrazit více v PubMed

Bartek, J. , Bartkova, J. , Lukas, J. , Staskova, Z. , Vojtesek, B. , L, .D. , 1993. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol. 169, 27–34. PubMed

Bartek, J. , Bartkova, J. , Lukas, J. , 2007. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773–7779. PubMed

Bartek, J. , Hodny, Z. , Lukas, J. , 2008. Cytokine loops driving senescence. Nat. Cell Biol. 10, 887–889. PubMed

Bartek, J. , Lukas, C. , Lukas, J. , 2004. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5, 792–804. PubMed

Bartkova, J. , Bakkenist, C.J. , Meyts, E.R. , Skakkebæk, N.E. , Sehested, M. , Lukas, J. , Kastan, M.B. , Bartek, J. , 2005. ATM activation in normal human tissues and testicular cancer. Cell Cycle 838–845. PubMed

Bartkova, J. , Falck, J. , Rajpert-De Meyts, E. , Skakkebaek, N.E. , Lukas, J. , Bartek, J. , 2001. Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours. Oncogene 20, 5897–5902. PubMed

Bartkova, J. , Hamerlik, P. , Stockhausen, M.-T. , Ehrmann, J. , Hlobilkova, a , Laursen, H. , Kalita, O. , Kolar, Z. , Poulsen, H.S. , Broholm, H. , Lukas, J. , Bartek, J. , 2010. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 29, 5095–5102. PubMed

Bartkova, J. , Horejsí, Z. , Koed, K. , Krämer, A. , Tort, F. , Zieger, K. , Guldberg, P. , Sehested, M. , Nesland, J.M. , Lukas, C. , Ørntoft, T. , Lukas, J. , Bartek, J. , 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870. PubMed

Bartkova, J. , Horejsí, Z. , Sehested, M. , Nesland, J.M. , Rajpert-De Meyts, E. , Skakkebaek, N.E. , Stucki, M. , Jackson, S. , Lukas, J. , Bartek, J. , 2007. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414–7422. PubMed

Bartkova, J. , Lukas, C. , Sørensen, C.S. , Rajpert-De Meyts, E. , Skakkebaek, N.E. , Lukas, J. , Bartek, J. , 2003. Deregulation of the RB pathway in human testicular germ cell tumours. J. Pathol. 200, 149–156. PubMed

Bartkova, J. , Rajpert-De Meyts, E. , Skakkebaek, N.E. , Lukas, J. , Bartek, J. , 2003. Deregulation of the G1/S-phase control in human testicular germ cell tumours. APMIS 111, 252–265. discussion 265–6 PubMed

Bartkova, J. , Rajpert-De Meyts, E. , Skakkebaek, N.E. , Lukas, J. , Bartek, J. , 2007. DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int. J. Androl. 30, 282–291. discussion 291 PubMed

Bartkova, J. , Rezaei, N. , Liontos, M. , Karakaidos, P. , Kletsas, D. , Issaeva, N. , Vassiliou, L.-V.F. , Kolettas, E. , Niforou, K. , Zoumpourlis, V.C. , Takaoka, M. , Nakagawa, H. , Tort, F. , Fugger, K. , Johansson, F. , Sehested, M. , Andersen, C.L. , Dyrskjot, L. , Ørntoft, T. , Lukas, J. , Kittas, C. , Helleday, T. , Halazonetis, T.D. , Bartek, J. , Gorgoulis, V.G. , 2006. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637. PubMed

Burrell, R. , McGranahan, N. , Bartek, J. , Swanton, C. , 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338–345. PubMed

Campisi, J. , d'Adda di Fagagna, F. , 2007. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740. PubMed

Di Micco, R. , Fumagalli, M. , Cicalese, A. , Piccinin, S. , Gasparini, P. , Luise, C. , Schurra, C. , Garre', M. , Nuciforo, P.G. , Bensimon, A. , Maestro, R. , Pelicci, P.G. , d'Adda di Fagagna, F. , 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642. PubMed

Evangelou, K. , Bartkova, J. , Kotsinas, a , Pateras, I.S. , Liontos, M. , Velimezi, G. , Kosar, M. , Liloglou, T. , Trougakos, I.P. , Dyrskjot, L. , Andersen, C.L. , Papaioannou, M. , Drosos, Y. , Papafotiou, G. , Hodny, Z. , Sosa-Pineda, B. , Wu, X.-R. , Klinakis, a , Ørntoft, T. , Lukas, J. , Bartek, J. , Gorgoulis, V.G. , 2013. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ. 20, 1485–1497. PubMed PMC

Gobel, U. , Schneider, D.T. , Calaminus, G. , Haas, R.J. , Schmidt, P. , Harms, D. , 2000. Review germ-cell tumors in childhood and adolescence. Ann. Oncol. 11, (3) 263–271. PubMed

Gorgoulis, V.G. , Vassiliou, L.F. , Karakaidos, P. , Zacharatos, P. , Kotsinas, A. , Liloglou, T. , Venere, M. , D, R.A. , Kastrinakis, N.G. , Levy, B. , Kletsas, D. , Yoneta, A. , Herlyn, M. , Kittas, C. , Halazonetis, T.D. , 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913. PubMed

Halazonetis, T.D. , Gorgoulis, V.G. , Bartek, J. , 2008. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355. PubMed

Hodny, Z. , Hubackova, S. , Bartek, J. , 2013. Cytokine-induced “bystander” senescence in DDR and immuno-surveillance. Oncotarget 4, 1552–1553. PubMed PMC

Hoei-Hansen, C.E. , Sehested, a , Juhler, M. , Lau, Y.-F.C. , Skakkebaek, N.E. , Laursen, H. , Rajpert-de Meyts, E. , 2006. New evidence for the origin of intracranial germ cell tumours from primordial germ cells: expression of pluripotency and cell differentiation markers. J. Pathol. 209, 25–33. PubMed

Hubackova, S. , Krejcikova, K. , Bartek, J. , Hodny, Z. , 2012. IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine “bystander senescence”. Aging (Albany. NY) 4, 932–951. PubMed PMC

Jackson, S.P. , Bartek, J. , 2009. Europe PMC Funders Group the DNA-damage response in human biology and disease. Nature 461, 1071–1078. PubMed PMC

Jørgensen, A. , Nielsen, J.E. , Almstrup, K. , Toft, B.G. , Petersen, B.L. , Rajpert-De Meyts, E. , 2013. Dysregulation of the mitosis-meiosis switch in testicular carcinoma in situ. J. Pathol. 229, 588–598. PubMed

Kastan, M.B. , Bartek, J. , 2004. Cell-cycle checkpoints and cancer. Nature 432, 316–323. PubMed

Koster, R. , van Vugt, M.A. , Timmer-Bosscha, H. , Gietema, J.A. , de, J.S. , 2013. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev. Mol. Med. 15, 12 PubMed

Lukas, C. , Bartkova, J. , Latella, L. , Falck, J. , Mailand, N. , Schroeder, T. , Sehested, M. , Lukas, J. , Bartek, J. , 2001. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation, yet correlates with tissue biology. Cancer Res. 61, 4990–4993. PubMed

Mosbech, C.H. , Rechnitzer, C. , Brok, J.S. , Rajpert-De Meyts, E. , Hoei-Hansen, C.E. , 2014. Recent advances in understanding the etiology and pathogenesis of pediatric germ cell tumors. J. Pediatr. Hematol. Oncol. 36, 263–270. PubMed

Oosterhuis, J.W. , Stoop, H. , Honecker, F. , Looijenga, L.H.J. , 2007. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int. J. Androl. 30, 256–263. discussion 263–4 PubMed

Rajpert-De Meyts, E. , Bartkova, J. , Samson, M. , Hoei-Hansen, C.E. , Frydelund-Larsen, L. , Bartek, J. , Skakkebaek, N.E. , 2003. The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 111, 267–278. PubMed

Rosenblum, M.K. , Matsutani, M. , VanMeir, E.G. , K., P. , C., W. , 2000. Pathology and Genetics of Tumours of the Nervous System, Chapter: CNS Germ Cell Tumours IARC Press (International Agency for Research on Cancer) 208–214.

Schneider, D.T. , Schuster, A.E. , Fritsch, M.K. , Pediatric, N. , Cell, G. , Hu, J. , Olson, T. , Lauer, S. , Go, U. , 2001. Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer Res. 7268–7276. PubMed

Scotting, P.J. , 2006. Are cranial germ cell tumours really tumours of germ cells?. Neuropathol. Appl. Neurobiol. 32, 569–574. PubMed

Sherr, C.J. , 2012. Ink4-Arf locus in cancer and aging. Wiley Interdiscip. Rev. Dev. Biol. 1, 731–741. PubMed PMC

Teilum, G. , 1965. Classification of endodermal sinus tumour (mesoblatoma vitellinum) and so-called “embryonal carcinoma” of the ovary. Acta Pathol. Microbiol. Scand. 64, 407–429. PubMed

Terashima, K. , Yu, A. , Chow, W.T. , Hsu, W.J. , Chen, P. , Wong, S. , Hung, Y.S. , Suzuki, T. , Nishikawa, R. , Matsutani, M. , Nakamura, H. , Ng, H. , Allen, J.C. , Aldape, K.D. , Su, J.M. , Adesina, A.M. , Leung, H.E. , Man, T. , Lau, C.C. , 2014. Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors. Pediatr. Blood Cancer 593–600. PubMed

Tort, F. , Bartkova, J. , Sehested, M. , Orntoft, T. , Lukas, J. , Bartek, J. , 2006. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res. 66, 10258–10263. PubMed

Velimezi, G. , Liontos, M. , Vougas, K. , Roumeliotis, T. , Bartkova, J. , Sideridou, M. , Dereli-Oz, A. , Kocylowski, M. , Pateras, I.S. , Evangelou, K. , Kotsinas, A. , Orsolic, I. , Bursac, S. , Cokaric-Brdovcak, M. , Zoumpourlis, V. , Kletsas, D. , Papafotiou, G. , Klinakis, A. , Volarevic, S. , Gu, W. , Bartek, J. , Halazonetis, T.D. , Gorgoulis, V.G. , 2013. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 15, 967–977. PubMed

Yamada, Y. , Coffman, C.R. , 2005. DNA damage-induced programmed cell death: potential roles in germ cell development. Ann. N. Y. Acad. Sci. 1049, 9–16. PubMed

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer